Oliveira-Nunes Maria Cecilia, Julião Glaucia, Menezes Aline, Mariath Fernanda, Hanover John A, Evaristo Joseph Albert Medeiros, Nogueira Fábio César Sousa, Dias Wagner Barbosa, de Abreu Pereira Denise, Carneiro Katia
Laboratory of Cell Proliferation and Differentiation, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Clin Proteomics. 2021 Apr 26;18(1):14. doi: 10.1186/s12014-021-09317-x.
Glioblastoma (GBM) is a grade IV glioma highly aggressive and refractory to the therapeutic approaches currently in use. O-GlcNAcylation plays a key role for tumor aggressiveness and progression in different types of cancer; however, experimental evidence of its involvement in GBM are still lacking. Here, we show that O-GlcNAcylation plays a critical role in maintaining the composition of the GBM secretome, whereas inhibition of OGA activity disrupts the intercellular signaling via microvesicles. Using a label-free quantitative proteomics methodology, we identified 51 proteins in the GBM secretome whose abundance was significantly altered by activity inhibition of O-GlcNAcase (iOGA). Among these proteins, we observed that proteins related to proteasome activity and to regulation of immune response in the tumor microenvironment were consistently downregulated in GBM cells upon iOGA. While the proteins IGFBP3, IL-6 and HSPA5 were downregulated in GBM iOGA cells, the protein SQSTM1/p62 was exclusively found in GBM cells under iOGA. These findings were in line with literature evidence on the role of p62/IL-6 signaling axis in suppressing tumor aggressiveness and our experimental evidence showing a decrease in radioresistance potential of these cells. Taken together, our findings provide evidence that OGA activity may regulate the p62 and IL-6 abundance in the GBM secretome. We propose that the assessment of tumor status from the main proteins present in its secretome may contribute to the advancement of diagnostic, prognostic and even therapeutic tools to approach this relevant malignancy.
胶质母细胞瘤(GBM)是一种IV级胶质瘤,具有高度侵袭性,对目前使用的治疗方法具有耐药性。O-连接的N-乙酰葡糖胺化(O-GlcNAcylation)在不同类型癌症的肿瘤侵袭性和进展中起关键作用;然而,其参与GBM的实验证据仍然缺乏。在这里,我们表明O-GlcNAcylation在维持GBM分泌组的组成中起关键作用,而抑制OGA活性会破坏通过微泡的细胞间信号传导。使用无标记定量蛋白质组学方法,我们在GBM分泌组中鉴定了51种蛋白质,其丰度因O-葡萄糖苷酶(iOGA)的活性抑制而显著改变。在这些蛋白质中,我们观察到,在iOGA处理后,GBM细胞中与蛋白酶体活性和肿瘤微环境中免疫反应调节相关的蛋白质持续下调。虽然IGFBP3、IL-6和HSPA5蛋白在GBM iOGA细胞中下调,但SQSTM1/p62蛋白仅在iOGA处理的GBM细胞中发现。这些发现与关于p62/IL-6信号轴在抑制肿瘤侵袭性中的作用的文献证据一致,并且我们的实验证据表明这些细胞的放射抗性潜力降低。综上所述,我们的发现提供了证据表明OGA活性可能调节GBM分泌组中p62和IL-6的丰度。我们建议,从其分泌组中存在的主要蛋白质评估肿瘤状态可能有助于推进针对这种相关恶性肿瘤的诊断、预后甚至治疗工具的发展。